128 related articles for article (PubMed ID: 28777969)
41. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization.
Nagaich U; Gulati N
Drug Deliv Transl Res; 2016 Jun; 6(3):289-98. PubMed ID: 27072979
[TBL] [Abstract][Full Text] [Related]
42. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
Liu R; Liu Z; Zhang C; Zhang B
J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
[TBL] [Abstract][Full Text] [Related]
43. Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting.
Meng F; Asghar S; Xu Y; Wang J; Jin X; Wang Z; Wang J; Ping Q; Zhou J; Xiao Y
Int J Pharm; 2016 Jun; 506(1-2):46-56. PubMed ID: 27094357
[TBL] [Abstract][Full Text] [Related]
44. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
45. PEGylated long circulating nanostructured lipid carriers for Amoitone B: preparation, cytotoxicity and intracellular uptake.
Luan J; Yang X; Chu L; Xi Y; Zhai G
J Colloid Interface Sci; 2014 Aug; 428():49-56. PubMed ID: 24910034
[TBL] [Abstract][Full Text] [Related]
46. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity.
How CW; Rasedee A; Manickam S; Rosli R
Colloids Surf B Biointerfaces; 2013 Dec; 112():393-9. PubMed ID: 24036474
[TBL] [Abstract][Full Text] [Related]
47. Physicochemical characterization of lycopene-loaded nanostructured lipid carrier formulations for topical administration.
Okonogi S; Riangjanapatee P
Int J Pharm; 2015 Jan; 478(2):726-35. PubMed ID: 25479097
[TBL] [Abstract][Full Text] [Related]
48. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
Pinheiro M; Ribeiro R; Vieira A; Andrade F; Reis S
Drug Des Devel Ther; 2016; 10():2467-75. PubMed ID: 27536067
[TBL] [Abstract][Full Text] [Related]
49. Topical phenytoin nanostructured lipid carriers: design and development.
Motawea A; Borg T; Abd El-Gawad AEH
Drug Dev Ind Pharm; 2018 Jan; 44(1):144-157. PubMed ID: 28956451
[TBL] [Abstract][Full Text] [Related]
50. [Preparation and characterization of oxaliplatin-loaded nanostructured lipid carriers].
Zhou H; Qiu LP; Yan XX; Li L; Li X; Wang L; Liu M; Wang DK
Yao Xue Xue Bao; 2010 Sep; 45(9):1177-82. PubMed ID: 21351576
[TBL] [Abstract][Full Text] [Related]
51. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology.
Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S
Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384
[TBL] [Abstract][Full Text] [Related]
52. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles.
Tiyaboonchai W; Limpeanchob N
Int J Pharm; 2007 Feb; 329(1-2):142-9. PubMed ID: 17000065
[TBL] [Abstract][Full Text] [Related]
53. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
54. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam.
Khurana S; Jain NK; Bedi PM
Life Sci; 2013 Nov; 93(21):763-72. PubMed ID: 24113071
[TBL] [Abstract][Full Text] [Related]
55. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
56. Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy.
Gupta PK; Jaiswal AK; Asthana S; Teja B V; Shukla P; Shukla M; Sagar N; Dube A; Rath SK; Mishra PR
Br J Pharmacol; 2015 Jul; 172(14):3596-610. PubMed ID: 25825339
[TBL] [Abstract][Full Text] [Related]
57. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
58. Effect of solid lipid's structure on nanostructured lipid carriers encapsulated with sun filter: characterisation, photo-stability and in vitro release.
Wang K; Zhang QJ; Miao YL; Luo SQ; Wang HC; Zhang WP
J Microencapsul; 2017 Feb; 34(1):104-110. PubMed ID: 28152634
[TBL] [Abstract][Full Text] [Related]
59. Antileishmanial Agents Co-loaded in Transfersomes with Enhanced Macrophage Uptake and Reduced Toxicity.
Zahid F; Batool S; Ud-Din F; Ali Z; Nabi M; Khan S; Salman O; Khan GM
AAPS PharmSciTech; 2022 Aug; 23(6):226. PubMed ID: 35970966
[TBL] [Abstract][Full Text] [Related]
60. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
